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Abstract
Background: Hospitals in Canada manage their formularies independently, yet many inpatients are discharged on
medications which will be purchased through publicly-funded programs. We sought to determine how much public money
could be saved on chronic medications if hospitals promoted the initiation of agents with the lowest outpatient formulary
prices.
Methods: We used administrative databases for the province of Ontario to identify patients initiated on a proton pump
inhibitor (PPI), angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) following hospital
admission from April 1
st 2008-March 31
st 2009. We assessed the cost to the Ontario Drug Benefit Program (ODB) over the
year following initiation and determined the cost savings if prescriptions were substituted with the least expensive agent in
each class.
Results: The cost for filling all PPI, ACE inhibitor and ARB prescriptions was $ 2.48 million, $968 thousand and $325 thousand
respectively. Substituting the least expensive agent could have saved $1.16 million (47%) for PPIs, $162 thousand (17%) for
ACE inhibitors and $14 thousand (4%) for ARBs over the year following discharge.
Interpretation: In a setting where outpatient prescriptions are publicly funded, harmonising outpatient formularies with
inpatient therapeutic substitution resulted in modest cost savings and may be one way to control rising pharmaceutical
costs.
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Introduction
Annual healthcare expenditures in Canada are on a steep
upward climb, reaching $ 191 billion in 2010 [1]. Medications
represent an increasing share of costs, currently about 16%. A few
classes of drugs account for the bulk of expenses [2]. For instance,
the annual cost of angiotensin-converting enzyme (ACE) inhibitors
in Canada doubled over the previous ten years to reach $ 956
million in 2006 [3]. In this climate, healthcare managers have
turned to therapeutic substitution and reference-based pricing in
order to contain costs [4,5]. While therapeutic substitution targets
agent selection by reducing formulary options, reference-based
pricing limits prescription reimbursement to the cost of the least
expensive equivalent drug. Canada’s provincial premiers have
even spoken of creating a national pharmaceutical purchasing
agency in order to take advantage of economies of scale [6].
Publicly-funded programs absorb the cost of a large proportion
of outpatient drug expenditures [2]. Past studies have shown that
what is prescribed in hospital drives ongoing prescription in the
community[7–10]. Hospitals depend on public funds yet negotiate
drug prices directly with suppliers or through group-purchasing
organisations[11–13]. In either case, medication prices negotiated
by hospitals may not match those of the public-payer’s outpatient
formulary. Suppliers can offer hospitals discounts on proprietary
drugs in order to secure a client-base. In-hospital therapeutic
substitution strategies may steer patients toward agents that are
inexpensive for the hospital, yet more expensive for public drug
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‘‘loss leaders’’; their favourable pricing in one instance is used to
generate profits later on. This can have a perverse effect on long-
term drug costs once in the community.
Even small differences in drug acquisition costs can be amplified
over time because of the long-term nature of chronic disease
therapy. A harmonisation strategy would employ therapeutic
substitution in order to direct inpatients toward the least expensive
outpatient agents. We sought to determine how much savings
could be achieved on selected chronic medications if hospitals
initiated agents with the lowest outpatient formulary prices.
Methods
Overview
We used population-based administrative data covering all
Ontario residents over the age of 65. Patients were selected if they
were initiated on an ACE inhibitor, angiotensin receptor blocker
(ARB), or proton pump inhibitor (PPI) following hospitalization.
We assessed the cost to the Ontario Drug Benefit Program (ODB)
over the year following initiation. We then compared this cost to
the equivalent cost if all medications were substituted with the least
expensive agent in that category. Our primary outcome was cost
savings if this least expensive agent was used. This study was
approved by the research ethics board of Sunnybrook Health
Sciences Centre in Toronto, Canada.
Participants
This study made use of the multiple linked healthcare databases
available through the Institute for Clinical Evaluative Sciences
(ICES). These data were linked via encrypted unique patient
identifiers. Consent for participation was not obtained from
individual patients. This administrative data is collected by
governmental agencies and shared with ICES for research
purposes. Data are protected and pooled in order to prevent
individuals from being identifiable. We combined information
from the Ontario Drug Benefit (ODB) database, the Canadian
Institute for Health Information Discharge Abstract Database
(CIHI-DAD), the Ontario Health Insurance Plan (OHIP) physi-
cian billing services database and the Registered Persons Database
(RPDP). The comprehensive nature of health insurance coverage
in Ontario allows consideration of these analyses as population-
based. Data extracted using our databases has been validated in
previous studies [14,15].
Our cohort included all individuals aged 66 and over who filled
a new prescription for an ACE inhibitor, ARB or PPI within 7
days following hospital discharge between April 1
st 2008 and
March 31
st 2009. Prescriptions filled within 7 days of hospital
discharge have been used previously as a surrogate marker of
discharge prescription [8]. These drug classes were analysed in
three separate cohorts.
ACE inhibitor, ARB and PPI medication classes were selected
for two reasons. These medications are typically used to treat
common chronic medical conditions frequently discovered during
hospitalization[16–19]. Furthermore, the classes contain multiple
agents often considered to be of similar efficacy and side effect
profile. These are also medication classes commonly targeted by
therapeutic substitution policies [20,21].
Information concerning dispensed medications was identified
using ODB claims. These data provide medication information
using a drug identification number (DIN) specific to each
medication and dose, as well as the quantity, days’ supply and
the total prescription cost. These data have proven reliable when
compared to pharmacy prescription audit [15]. The ODB
program provides outpatient medication coverage to patients over
age 65. As part of this program, patients make a fixed per-
prescription co-payment and high-income patients also pay a $100
annual deductible [22].
Inclusions and Exclusions
In each of the three medication categories, patients were
excluded if the prescription was for a combination agent or if they
had filled a prescription for a medication within the same class in
the year prior to admission. Patients were excluded from the ACE
inhibitor group if they received captopril because it requires
multiple daily dosing and as such is markedly different from the
other ACE inhibitors. Patients were excluded from the PPI group
if they also received clopidogrel because of the possibility that drug
interactions were guiding medication selection [23–26].
In order to capture the effect of one admission, patients
transferred to another institution were excluded. Patients with an
index admission of more than 30 days were also excluded as these
patients may differ in their medication usage. For instance, a longer
admission may increase likelihood of multiple agents being tried
within a category.
Patient Characteristics
We collected information on age, sex and socioeconomic status
(low versus high income based on co-payment to ODB). We also
recorded Charlson comorbidity index [27], type of hospital setting
(urban, academic) and length of hospital stay. The number of
patients in long term care before and after index admission was
also recorded.
Outcome
The primary outcome was cost of therapy over the year
following hospital discharge. Net savings to the ODB if the
discharge medication was substituted with a less expensive agent
from the same class were then calculated. A secondary outcome
measurement was the cost of inpatient coverage of medication
costs based on ODB prices.
Calculation of Potential Savings
Real cost of therapy was obtained directly from ODB claims.
This was compared to the theoretical cost of therapy using an
equivalent dose of the least expensive agent in that class.
The least expensive agent within each class was identified using
ODB formulary prices in effect from April 1
st 2008 to March 31st
2010 [28]. Within each class, prices were compared using
equivalent doses. The theoretical cost of therapy with this agent
was then determined by multiplying the total number of pills
dispensed by the unit cost of the inexpensive agent as listed on the
formulary. Where the unit cost varied over our time period, we
used the price in effect for the greatest proportion.
Equivalent dose selection was based on the World Health
Organisation’s Defined Daily Doses [29]. Doses were modified to
reflect available formulations (see Tables S1, S2 and S3). When an
equivalent dose formulation was unavailable (eg: enalapril 2.5 mg
in ramipril equivalents) then the closest dose match was used. For
a low dose, this was the next highest dose; for a high dose, two tabs
of the highest dose were used.
A secondary analysis calculated the maximum cost to the
provincial drug plan of covering in-hospital medications. This was
obtained by multiplying total length of stay by the daily cost of the
first discharge prescription agent. This assumes the discharge
agent was administered every day of the hospitalisation period.
The daily cost with the discharge agent was chosen rather than
Harmonising Hospital and Community Formularies
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make this estimate more realistic.
Results
The mean age was similar in the three groups, 78–79 years
(Table 1). Most patients had co-morbid conditions as evidenced by
Charlson score, and median length of stay was 6 days. Of the
patients alive at one year following discharge, 44% were still filling
prescriptions for the discharge PPI, and 59% were filling
prescriptions for the discharge ACE inhibitor and ARB agents.
For the three groups in the year following discharge, hospital
readmission rates were 40–43% and 14–20% of patients died.
Proton Pump Inhibitors
A total of 7892 patients were initiated on a PPI. Out of a mean
217 PPI days filled per patient, 194 (89%) were for the original
discharge agent. During the follow-up year, 14.5% of patients
filled a prescription for a PPI other than the discharge agent. At
one year following discharge, 44.5% of living patients were on the
original discharge agent. The total cost for filling all PPI
prescriptions over the year following discharge was $ 2.48 million
(Table 2). The least expensive PPI (rabeprazole, Table 3) was
dispensed to 36% of patients (Figure 1). The most expensive PPI
(lansoprazole) was dispensed to 39% of patients. The calculated
cost savings generated by substituting all filled PPI prescriptions
with the least expensive agent was $ 1.16 million (47%). If the PPI
was directly funded for all the applicable hospitalised admissions,
this would cost an additional $ 109 thousand.
ACE Inhibitors
A total of 6802 patients were initiated on an ACE inhibitor. Out
of a mean 278 ACE inhibitor days filled per patient, 272 (98%)
were for the original discharge agent. During the follow-up year,
3.5% of patients filled a prescription for an ACE inhibitor other
than the discharge agent. At one year following discharge, 59.3%
of living patients were on the original discharge agent. The total
cost of supplying all new ACE inhibitor prescriptions over the
following year was $ 968 thousand (Table 2). The least expensive
ACE inhibitors were lisinopril and ramipril. While 78% of patients
were discharged on ramipril, only 2% were started on lisinopril
(Figure 2). Fifteen percent of patients were discharged on
perindopril, which was proprietary and one of the most expensive
agents (Table 3). The calculated cost savings by substituting all
filled ACE inhibitor prescriptions for lisinopril was $ 121 thousand
(13%). Replacing all ACE inhibitor prescriptions with ramipril
yielded cost savings of $162 thousand (17%). Supplying ACE
inhibitors to these patient in hospital would cost an additional $ 25
thousand.
Angiotensin Receptor Blockers
A total 963 patients were initiated on an ARB. Out of a mean
277 ARB days filled per patient, 269 (97%) were for the original
Table 1. Patient characteristics and prescription outcomes for PPI, ACE inhibitor and ARB groups.
PPI* ACE inhibitor { ARB{
Total in Group, n 7 892 6 802 963
Age at Index Date, Median (IQR), y 78 (72–84) 78 (72–84) 79 (73–84)
Female sex, no. (%) 4 117 (52.2) 3 463 (50.9) 563 (58.5)
Low-income status, No. (%) 1 913 (24.2) 1546 (22.7) 252 (26.2)
Charlson index, n (%)1
0 1 927 (24.4) 1172 (17.2) 230 (23.9)
1 2 079 (26.3) 2 511 (36.9) 274 (28.5)
$2 3 886 (49.2) 3 119 (45.9) 459 (47.7)
Urban Hospital Setting n (%) 7 251 (91.9) 6 247 (91.8) 869 (90.3)
Teaching Hospital n (%) 1 710 (21.7) 1 774 (26.1) 147 (15.3)
Median length of Stay During Index n (IQR) 6(3–11) 6 (3–10) 6 (3–10)
Admitted from Long-term care, n (%) 621 (7.9) 402 (5.9) 53 (5.5)
Discharged to Long-term care, n (%) 810 (10.3) 514 (7.6) 78 (8.1)
Follow up within 1 year of discharge: PPI* ACE inhibitor { ARB{
Days survived, mean 6 SD 317.696105.63 334.47685.86 332.69687.83
Died within 365 days of Discharge, n (%) 1 580 (20.0) 958 (14.1) 148 (15.4)
Patients getting 2+ different drugs in same class, n (%) 1 146 (14.5) 239 (3.5) 39 (4.0)
Patients on first prescribed agent at one year following discharge, n (% of
alive)
2 806 (44.5) 3464 (59.3) 485 (59.5)
Patients on any agent in class at one year following discharge, n (% of alive)3 373 (53.4) 3599 (61.6) 509 (62.5)
Patients readmitted to hospital, n (%) 3 420 (43.3) 2 748 (40.4) 414 (43.0)
Total days in Hospital, mean 6 SD 19.51627.52 17.19623.97 20.30636.76
*Proton pump inhibitor: omeprazole, pantoprazole, lansoprazole or rabeprazole.
{Angiotensin-converting enzyme inhibitor: ramipril, enalapril (maleate and sodium), quinapril, fosinopril, lisinopril, benazepril, perindopril, cilazapril or trandolapril.
{Angiotensin receptor blocker: losartan, candesartan, irbesartan, valsartan, telmisartan or eprosartan.
1As defined by Charlson comorbidity index [26].
doi:10.1371/journal.pone.0039737.t001
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a prescription for an ARB other than the discharge agent. At one
year following discharge, 59.5% of living patients were on the
original discharge agent. The total cost for filling all ARB
prescriptions over the following year was $ 325 Thousand
(Table 2). Eprosartan is the least expensive agent at the standard
daily dose, yet does not provide as many dose formulations as
other ARBs and no patients in our cohort were discharged on this
medication. Candesartan was the least expensive option with
multiple dosing options (Table 3), and it represented 30% of first
prescriptions (Figure 3). The most expensive agent (losartan) cost
9% more than the equivalent dose of candesartan (Table 3).
Replacing all ARB prescriptions with the equivalent dose of
candesartan would have saved $14 thousand (4%). Supplying
ARBs to these patients in hospital would have cost an additional $
8.5 thousand at a maximum.
Discussion
Our study used administrative databases to determine the
potential cost savings if selected drugs initiated in hospital were
substituted with the least expensive agent in each class. We found
that the vast majority of people continued their prescription
following hospital discharge. Agent selection in some drug classes
tended to favour the extremes; there were high prescription rates
for both inexpensive and more expensive, proprietary agents. Our
analysis showed that if the least expensive medication had been
selected in hospital, $ 1.3 Million could have been saved over one
year following discharge. The cost of direct inpatient drug
coverage would have been less than the generated savings in all
groups and less than 15% of savings for the PPI and ACE inhibitor
groups.
Overall, theoretical cost-savings were modest at 35%. These
were highest in the PPI group, where only 36% of patients were
prescribed the least expensive agent at discharge. In our study
period, this class also showed the greatest variation in unit price, as
both generic and proprietary agents were simultaneously available.
The extent of savings were not as great for ACE inhibitors or
ARBs. This might be explained by smaller price differences
between agents as well as higher market share of inexpensive
agents during our study period.
Figure 1. First Proton Pump Inhibitor Prescription Filled After Hospital Discharge.
doi:10.1371/journal.pone.0039737.g001
Table 2. Cost of discharge prescriptions, potential Savings with inexpensive agent and cost of inpatient drug coverage for PPI,
ACE inhibitors and ARBs.
PPI* ACE inhibitor
{ ARB
{
Number of patients, n 7 892 6 802 963
Total number of ‘‘days supplied’’ over year following discharge, n 1 712 782 1 896 288 266 518
Cost over year following discharge, $ CAN $ 2 475 448 $968 419 $324 568
Calculated cost if use inexpensive agent instead, $ CAN (agent) $1 315 660 (rabeprazole) $ 806 874 (ramipril) $ 310 644 (candesartan)
Potential savings, $ CAN (% of real cost) $1 159 788(47) $161 545 (17) $ 13 925 (4)
Total days in hospital during index admission, n 65 935 51 302 7 190
Cost of in-hospital coverage for first discharge agent, $ CAN $ 109 099 $ 24 922 $ 8 578
*Proton pump inhibitor: omeprazole, pantoprazole, lansoprazole or rabeprazole.
{Angiotensin-converting enzyme inhibitor: ramipril, enalapril (maleate and sodium), quinapril, fosinopril, lisinopril, benazepril, perindopril, cilazapril or trandolapril.
{Angiotensin receptor blocker: losartan, candesartan, irbesartan, valsartan, telmisartan or eprosartan.
doi:10.1371/journal.pone.0039737.t002
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In Ontario, only higher-income patients pay a $100 annual
deductible before ODB coverage occurs. Copayments to the ODB
are a set per-prescription cost that does not vary depending on
agent selection or drug price [22]. For this reason, prescriber
preference becomes the main driver of long-term costs. Formulary
harmonisation is one way to change prescriber practices to reduce
long-term public drug costs.
‘‘Harmonization’’ of inpatient and outpatient formularies does
occur elsewhere. Some Health Maintenance Organisations in the
United States combine purchasing for their hospitals and clinics in
order to decrease overall acquisition costs [30]. New Zealand has
also moved to a model of central contract negotiations for both
inpatient and outpatient medications. While this strategy resulted
in cost savings, hospital pharmacists cited loss of drug access,
inferior formulary products as well as occasional drug shortages as
disadvantages of this system [31].
Harmonising inpatient prescriptions with outpatient formular-
ies may require provincially-administered therapeutic substitution
policies to encourage selection of less expensive agents. Thera-
peutic substitution has been criticized for a few reasons. Many
question the notion of a ‘‘class effect’’, as data have shown
within-class mortality differences [32]. This issue has been central
to some well-publicized legal cases pitting governmental agencies
against the pharmaceutical industry [33]. Others claim that
therapeutic substitution limits physician autonomy [34]. Howev-
er, opportunities for special requests can help to keep options
open for prescribing physicians.
Reference-based pricing is a drug-funding policy that limits
medication reimbursement to the price of the least expensive agent
within a class. In British Columbia, this strategy succeeded in
shifting prescription trends toward cheaper agents [35,36]. A
report from the Ministry of Health of Manitoba suggested that
a reference-based pricing model would have saved Manitoba’s
Pharmacare $ 2.2 Million (28%) in 2000–2001 on ACE inhibitors
and ARBs alone [37]. The savings were further increased by
adding mandated reduced generic pricing as occurs in several
provinces [38,39].
Provincial drug programs could also achieve savings if they
implemented reference-based pricing for the drugs listed on the
outpatient formulary. However, without formulary harmonisation,
agent selection might be changed following hospital discharge.
The advantage of harmonisation over a policy of reference-based
pricing alone is that there is no need to undergo any ‘‘switching’’
process. Continuation requires no further cost or intervention, and
as a result non-adherence may be less likely. Nonetheless,
reference-based pricing has the advantage of targeting all new
prescriptions rather than just those initiated in hospital.
Strengths of this study include its large sample size. Using new
prescriptions filled seven days post discharge allowed us to capture
the cost of medications prescribed after hospital admission only
[8,40]. By studying three different drug classes, we were better able
to evaluate hospital discharge prescription practices, and to
Table 3. Cost in $ CAN of one pill at equivalent doses for PPI, ACE inhibitors and ARB groups*.
Least expensive agent, dose (cost) Commonly prescribed agents, dose (cost) Most expensive agent, dose (cost)
PPI
{ Rabeprazole 20 mg ($0.65) Pantoprazole 40 mg ($0.98–1.96) Lansoprazole 30 mg ($1.0–2.0)
ACE inhibitor
{ Lisinopril 10 mg ($0.32) Ramipril 2.5 mg ($ 0.38) Perindopril 4 mg
($ 0.75–0.78)
Quinapril 10 mg ($0.85)
ARB Candesartan 8 mg ($1.14) Valsartan 80 mg ($1.16–1.18) Losartan 50 mg ($1.21–1.25)
*Cost obtained from Ontario Drug Benefit formulary prices in effect from April 1
st 2008 to March 31st 2010 [27].
{Proton pump inhibitor: omeprazole, pantoprazole, lansoprazole or rabeprazole.
{Angiotensin-converting enzyme inhibitor: ramipril, enalapril (maleate and sodium), quinapril, fosinopril, lisinopril, benazepril, perindopril, cilazapril or trandolapril.
"Angiotensin receptor blocker: losartan, candesartan, irbesartan, valsartan, telmisartan or eprosartan.
doi:10.1371/journal.pone.0039737.t003
Figure 2. First Angiotensin-Converting Enzyme Inhibitor Prescription Filled After Hospital Discharge.
doi:10.1371/journal.pone.0039737.g002
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worthwhile. Our cost calculation was done using precise data,
verified against formulary prices in effect at the time. Our cost-
comparison is time-specific and sensitive to cost and policy
changes. For example, recent ODB pricing policy has further
reduced generic drug prices to 25% of the brand price [38]. As
new drugs emerge, wide price gaps between proprietary and
generic agents within a class will likely be a recurring phenom-
enon. While the degree of cost-savings generated by a harmonisa-
tion policy may vary by drug class, the concept remains valid for
all price points. Furthermore, these medications are considered to
be chronic therapies. As such, savings would be ongoing for many
years.
Limitations
While the harmonisation model rests on the inpatient formu-
lary, our study is limited by the fact that we only have data on
prescriptions filled by outpatients. We were not able to ascertain
inpatient drug therapy using the administrative data available to
us, and used prescriptions filled 7 days post-discharge as a marker
of inpatient medication selection. Using such a close temporal
association reduces the likelihood of contamination by outpatient
prescribers, however this cannot be entirely ruled out.
Furthermore, our estimate of cost-savings in the harmonisation
model may be overestimated. A small number of patients who
changed agents during the year of follow-up would presumably
escape the influence of the inpatient formulary on long-term
therapy. This effect may be greatest in the PPI group, where 11%
of PPI days were filled with a non-discharge PPI.
Our ability to predict cost-savings is also limited by our lack of
knowledge about inpatient medication costs. We do not know if
local negotiations result in lower prices than those quoted by the
ODB, because information about supplier contracts with hospitals
is confidential [41]. While a harmonisation policy could save
money on certain medications, it is possible that costs for other (eg:
intravenous or uninsured) medications would increase as a result of
lost contracts or bundling agreements with pharmaceutical
suppliers. Nonetheless, the ODB possibly obtains more favorable
pricing on most medications, given that it has more purchasing
power.
Conclusion
For selected chronic disease medications, we found that drug
selection in hospital was strongly associated with long-term
outpatient prescribing. Yet it was not reflective of outpatient
prices. The least expensive agent in the class was seldom chosen.
Our results show that this can result in incremental outpatient
costs. In-hospital selection of agents with the lowest outpatient
prices is one way to limit the long-term costs of chronic drug
therapy. In an era of rising healthcare costs a harmonised
approach makes economic sense.
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